Vaccination with a live attenuated cytomegalovirus devoid of a protein kinase R inhibitory gene results in reduced maternal viremia and improved pregnancy outcome in a Guinea pig congenital infection model

Journal of Virology

Volumn 89, Issue 19, 2015, Pages 9727-9738

  Schleiss, Mark R ^a   Bierle, Craig J ^a   Swanson, Elizabeth C ^a   McVoy, Michael A ^b   Wang, Jian Ben ^b   Al Mahdi, Zainab ^b   Geballe, Adam P ^c  

^a UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^b VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; CYTOMEGALOVIRUS VACCINE; LIVE VACCINE; NEUTRALIZING ANTIBODY; PROTEIN SERINE THREONINE KINASE; VIRUS VACCINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONGENITAL INFECTION; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GENE DELETION; GENE STRUCTURE; GENE TARGETING; GP145 GENE; GUINEA PIG; IMMUNE RESPONSE; IMMUNOGENICITY; INFECTION RATE; INOCULATION; LOW DRUG DOSE; MORTALITY; NONHUMAN; PREGNANCY OUTCOME; PRIORITY JOURNAL; PUP (RODENT); SALIVARY GLAND; VIREMIA; VIRUS GENE; VIRUS GENOME; VIRUS LOAD; VIRUS REPLICATION; VIRUS TRANSMISSION; ANIMAL; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; DEFICIENCY; GENETICS; IMMUNOLOGY; PREGNANCY; PROCEDURES; VACCINATION;

ANIMALS; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; FEMALE; GUINEA PIGS; PREGNANCY; PREGNANCY OUTCOME; PROTEIN-SERINE-THREONINE KINASES; VACCINATION; VACCINES, ATTENUATED; VIRAL VACCINES; VIREMIA;

EID: 84941007394     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.01419-15     Document Type: Article

References (56)

1. Griffiths P, Baraniak I, Reeves M. 2015. The pathogenesis of human cytomegalovirus. J Pathol 235:288-297. http://dx.doi.org/10.1002/path.4437.
2. Boeckh M, Geballe AP. 2011. Cytomegalovirus: pathogen, paradigm, and puzzle. J Clin Invest 121:1673-1680. http://dx.doi.org/10.1172/JCI45449.
3. Arvin AM, Fast P, Myers M, Plotkin S, Rabinovich R. 2004. Vaccine development to prevent cytomegalovirus disease: report from the National Vaccine Advisory Committee. Clin Infect Dis 39:233-239. http://dx.doi.org/10.1086/421999.
4. Khanna R, Diamond DJ. 2006. Human cytomegalovirus vaccine: time to look for alternative options. Trends Mol Med 12:26-33. http://dx.doi.org/10.1016/j.molmed.2005.11.006.
5. Sung H, Schleiss MR. 2010. Update on the current status of cytomegalovirus vaccines. Expert Rev Vaccines 9:1303-1314. http://dx.doi.org/10.1586/erv.10.125.
6. Fu TM, An Z, Wang D. 2014. Progress on pursuit of human cytomegalovirus vaccines for prevention of congenital infection and disease. Vaccine 32:2525-2533. http://dx.doi.org/10.1016/j.vaccine.2014.03.057.
7. McVoy MA. 2013. Cytomegalovirus vaccines. Clin Infect Dis 57(Suppl 4):S196-S199. http://dx.doi.org/10.1093/cid/cit587.
8. Pass RF, Zhang C, Evans A, Simpson T, Andrews W, Huang ML, Corey L, Hill J, Davis E, Flanigan C, Cloud G. 2009. Vaccine prevention of maternal cytomegalovirus infection. N Engl J Med 360:1191-1199. http://dx.doi.org/10.1056/NEJMoa0804749.
9. Kharfan-Dabaja MA, Boeckh M, Wilck MB, Langston AA, Chu AH, Wloch MK, Guterwill DF, Smith LR, Rolland AP, Kenney RT. 2012. A novel therapeutic cytomegalovirus DNA vaccine in allogeneic haemopoietic stem-cell transplantation: a randomised, double-blind, placebocontrolled, phase 2 trial. Lancet Infect Dis 12:290-299. http://dx.doi.org/10.1016/S1473-3099(11)70344-9.
10. Griffiths PD, Stanton A, McCarrell E, Smith C, Osman M, Harber M, Davenport A, Jones G, Wheeler DC, O'Beirne J, Thorburn D, Patch D, Atkinson CE, Pichon S, Sweny P, Lanzman M, Woodford E, Rothwell E, Old N, Kinyanjui R, Haque T, Atabani S, Luck S, Prideaux S, Milne RS, Emery VC, Burroughs AK. 2011. Cytomegalovirus glycoprotein-B vaccine with MF59 adjuvant in transplant recipients: a phase 2 randomised placebo-controlled trial. Lancet 377:1256-1263. http://dx.doi.org/10.1016/S0140-6736(11)60136-0.
11. Plotkin SA, Smiley ML, Friedman HM, Starr SE, Fleisher GR, Wlodaver C, Dafoe DC, Friedman AD, Grossman RA, Barker CF. 1984. Townevaccine-induced prevention of cytomegalovirus disease after renal transplants. Lancet i:528-530.
12. Plotkin SA, Starr SE, Friedman HM, Brayman K, Harris S, Jackson S, Tustin NB, Grossman R, Dafoe D, Barker C. 1991. Effect of Towne live virus vaccine on cytomegalovirus disease after renal transplant. A controlled trial. Ann Intern Med 114:525-531.
13. Adler SP, Starr SE, Plotkin SA, Hempfling SH, Buis J, Manning ML, Best AM. 1995. Immunity induced by primary human cytomegalovirus infection protects against secondary infection among women of childbearing age. J Infect Dis 171:26-32. http://dx.doi.org/10.1093/infdis/171.1.26.
14. Heineman TC, Schleiss M, Bernstein DI, Spaete RR, Yan L, Duke G, Prichard M, Wang Z, Yan Q, Sharp MA, Klein N, Arvin AM, Kemble G. 2006. A phase 1 study of 4 live, recombinant human cytomegalovirus Towne/Toledo chimeric vaccines. J Infect Dis 193:1350-1360. http://dx.doi.org/10.1086/503365.
15. Jacobson MA, Adler SP, Sinclair E, Black D, Smith A, Chu A, Moss RB, Wloch MK. 2009. A CMV DNA vaccine primes for memory immune responses to live-attenuated CMV (Towne strain). Vaccine 27:1540-1548. http://dx.doi.org/10.1016/j.vaccine.2009.01.006.
16. Jacobson MA, Sinclair E, Bredt B, Agrillo L, Black D, Epling CL, Carvidi A, Ho T, Bains R, Adler SP. 2006. Safety and immunogenicity of Towne cytomegalovirus vaccine with or without adjuvant recombinant interleukin-12. Vaccine 24:5311-5319. http://dx.doi.org/10.1016/j.vaccine.2006.04.017.
17. Dolan A, Cunningham C, Hector RD, Hassan-Walker AF, Lee L, Addison C, Dargan DJ, McGeoch DJ, Gatherer D, Emery VC, Griffiths PD, Sinzger C, McSharry BP, Wilkinson GW, Davison AJ. 2004. Genetic content of wild-type human cytomegalovirus. J Gen Virol 85:1301-1312. http://dx.doi.org/10.1099/vir.0.79888-0.
18. Freed DC, Tang Q, Tang A, Li F, He X, Huang Z, Meng W, Xia L, Finnefrock AC, Durr E, Espeseth AS, Casimiro DR, Zhang N, Shiver JW, Wang D, An Z, Fu TM. 2013. Pentameric complex of viral glycoprotein H is the primary target for potent neutralization by a human cytomegalovirus vaccine. Proc Natl Acad Sci U S A 110:E4997-E5005. http://dx.doi.org/10.1073/pnas.1316517110.
19. Söderberg-Nauclér C. 2006. Does cytomegalovirus play a causative role in the development of various inflammatory diseases and cancer? J Intern Med 259:219-246. http://dx.doi.org/10.1111/j.1365-2796.2006.01618.x.
20. Söderberg-Nauclér C. 2012. Autoimmunity induced by human cytomegalovirus in patients with systemic lupus erythematosus. Arthritis Res Ther 14:101. http://dx.doi.org/10.1186/ar3525.
21. Schleiss MR, Lacayo JC, Belkaid Y, McGregor A, Stroup G, Rayner J, Alterson K, Chulay JD, Smith JF. 2007. Preconceptual administration of an alphavirus replicon UL83 (pp65 homolog) vaccine induces humoral and cellular immunity and improves pregnancy outcome in the guinea pig model of congenital cytomegalovirus infection. J Infect Dis 195:789-798. http://dx.doi.org/10.1086/511982.
22. Schleiss MR, Bourne N, Stroup G, Bravo FJ, Jensen NJ, Bernstein DI. 2004. Protection against congenital cytomegalovirus infection and disease in guinea pigs, conferred by a purified recombinant glycoprotein B vaccine. J Infect Dis 189:1374-1381. http://dx.doi.org/10.1086/382751.
23. Crumpler MM, Choi KY, McVoy MA, Schleiss MR. 2009. A live guinea pig cytomegalovirus vaccine deleted of three putative immune evasion genes is highly attenuated but remains immunogenic in a vaccine/challenge model of congenital cytomegalovirus infection. Vaccine 27: 4209-4218. http://dx.doi.org/10.1016/j.vaccine.2009.04.036.
24. Mohr CA, Cicin-Sain L, Wagner M, Sacher T, Schnee M, Ruzsics Z, Koszinowski UH. 2008. Engineering of cytomegalovirus genomes for recombinant live herpesvirus vaccines. Int J Med Microbiol 298:115-125. http://dx.doi.org/10.1016/j.ijmm.2007.07.008.
25. Yang D, Alam Z, Cui X, Chen M, Sherrod CJ, McVoy MA, Schleiss MR, Dittmer DP. 2014. Complete genome sequence of cell culture-attenuated guinea pig cytomegalovirus cloned as an infectious bacterial artificial chromosome. Genome Announc 2(5):e00928-14. http://dx.doi.org/10.1128/genomeA.00928-14.
26. Marshall EE, Geballe AP. 2009. Multifaceted evasion of the interferon response by cytomegalovirus. J Interferon Cytokine Res 29:609-619. http://dx.doi.org/10.1089/jir.2009.0064.
27. Marshall EE, Bierle CJ, Brune W, Geballe AP. 2009. Essential role for either TRS1 or IRS1 in human cytomegalovirus replication. J Virol 83: 4112-4120. http://dx.doi.org/10.1128/JVI.02489-08.
28. Hakki M, Marshall EE, De Niro KL, Geballe AP. 2006. Binding and nuclear relocalization of protein kinase R by human cytomegalovirus TRS1. J Virol 80:11817-11826. http://dx.doi.org/10.1128/JVI.00957-06.
29. Child SJ, Hanson LK, Brown CE, Janzen DM, Geballe AP. 2006. Double-stranded RNA binding by a heterodimeric complex of murine cytomegalovirus m142 and m143 proteins. J Virol 80:10173-10180. http://dx.doi.org/10.1128/JVI.00905-06.
30. Child SJ, Geballe AP. 2009. Binding and relocalization of protein kinase R by murine cytomegalovirus. J Virol 83:1790-1799. http://dx.doi.org/10.1128/JVI.01484-08.
31. Budt M, Niederstadt L, Valchanova RS, Jonjic S, Brune W. 2009. Specific inhibition of the PKR-mediated antiviral response by the murine cytomegalovirus proteins m142 and m143. J Virol 83:1260-1270. http://dx.doi.org/10.1128/JVI.01558-08.
32. Valchanova RS, Picard-Maureau M, Budt M, Brune W. 2006. Murine cytomegalovirus m142 and m143 are both required to block protein kinase R-mediated shutdown of protein synthesis. J Virol 80:10181-10190. http://dx.doi.org/10.1128/JVI.00908-06.
33. Bierle CJ, Schleiss MR, Geballe AP. 2012. Antagonism of the protein kinase Rpathway by the guinea pig cytomegalovirus US22-family gene gp145. Virology 433:157-166. http://dx.doi.org/10.1016/j.virol.2012.08.005.
34. Chou J, Roizman B. 1992. The gamma 1(34.5) gene of herpes simplex virus 1 precludes neuroblastoma cells from triggering total shutoffof protein synthesis characteristic of programed cell death in neuronal cells. Proc Natl Acad Sci U S A 89:3266-3270. http://dx.doi.org/10.1073/pnas.89.8.3266.
35. Denzler KL, Babas T, Rippeon A, Huynh T, Fukushima N, Rhodes L, Silvera PM, Jacobs BL. 2011. Attenuated NYCBH vaccinia virus deleted for the E3L gene confers partial protection against lethal monkeypox virus disease in cynomolgus macaques. Vaccine 29:9684-9690. http://dx.doi.org/10.1016/j.vaccine.2011.09.135.
36. Spector FC, Kern ER, Palmer J, Kaiwar R, Cha TA, Brown P, Spaete RR. 1998. Evaluation of a live attenuated recombinant virus RAV 9395 as a herpes simplex virus type 2 vaccine in guinea pigs. J Infect Dis 177:1143-1154. http://dx.doi.org/10.1086/515278.
37. Schleiss MR, Choi KY, Anderson J, Mash JG, WettendorffM, Mossman S, Van Damme M. 2014. Glycoprotein B (gB) vaccines adjuvanted with AS01 or AS02 protect female guinea pigs against cytomegalovirus (CMV) viremia and offspring mortality in a CMV-challenge model. Vaccine 32: 2756-2762. http://dx.doi.org/10.1016/j.vaccine.2013.07.010.
38. Schleiss MR. 2008. Comparison of vaccine strategies against congenital CMVinfection in the guinea pig model. J Clin Virol 41:224-230. http://dx.doi.org/10.1016/j.jcv.2007.10.008.
39. Cui X, McGregor A, Schleiss MR, McVoy MA. 2008. Cloning the complete guinea pig cytomegalovirus genome as an infectious bacterial artificial chromosome with excisable origin of replication. J Virol Methods 149:231-239. http://dx.doi.org/10.1016/j.jviromet.2008.01.031.
40. McGregor A, Schleiss MR. 2001. Molecular cloning of the guinea pig cytomegalovirus (GPCMV) genome as an infectious bacterial artificial chromosome (BAC) in Escherichia coli. Mol Genet Metab 72:15-26. http://dx.doi.org/10.1006/mgme.2000.3102.
41. Leviton MP, Lacayo JC, Choi KY, Hernandez-Alvarado N, Wey A, Schleiss MR. 2013. An attenuated cytomegalovirus vaccine with a deletion of a viral chemokine gene is protective against congenital CMV transmission in a guinea pig model. Clin Dev Immunol 2013:906948. http://dx.doi.org/10.1155/2013/906948.
42. Nozawa N, Yamamoto Y, Fukui Y, Katano H, Tsutsui Y, Sato Y, Yamada S, Inami Y, Nakamura K, Yokoi M, Kurane I, Inoue N. 2008. Identification of a 1.6 kb genome locus of guinea pig cytomegalovirus required for efficient viral growth in animals but not in cell culture. Virology 379:45-54. http://dx.doi.org/10.1016/j.virol.2008.06.018.
43. Gnanandarajah JS, Gillis PA, Hernandez-Alvarado N, Higgins L, Markowski TW, Sung H, Lumley S, Schleiss MR. 2014. Identification by mass spectrometry and immune response analysis of guinea pig cytomegalovirus (GPCMV) pentameric complex proteins GP129, 131 and 133. Viruses 6:727-751. http://dx.doi.org/10.3390/v6020727.
44. Auerbach M, Yan D, Fouts A, Xu M, Estevez A, Austin CD, Bazan F, Feierbach B. 2013. Characterization of the guinea pig CMV gH/gL/GP129/GP131/GP133 complex in infection and spread. Virology 441:75-84. http://dx.doi.org/10.1016/j.virol.2013.03.008.
45. Wang JB, McVoy MA. 2008. Mutagenesis of the murine cytomegalovirus M56terminase gene. J Gen Virol 89:2864-2868. http://dx.doi.org/10.1099/vir.0.2008/003137-0.
46. Cui X, McGregor A, Schleiss MR, McVoy MA. 2009. The impact of genome length on replication and genome stability of the herpesvirus guinea pig cytomegalovirus. Virology 386:132-138. http://dx.doi.org/10.1016/j.virol.2008.12.030.
47. Schleiss MR, Bernstein DI, McVoy MA, Stroup G, Bravo F, Creasy B, McGregor A, Henninger K, Hallenberger S. 2005. The non-nucleoside antiviral, BAY 38-4766, protects against cytomegalovirus (CMV) disease and mortality in immunocompromised guinea pigs. Antiviral Res 65:35-43. http://dx.doi.org/10.1016/j.antiviral.2004.09.004.
48. Jentarra GM, Heck MC, Youn JW, Kibler K, Langland JO, Baskin CR, Ananieva O, Chang Y, Jacobs BL. 2008. Vaccinia viruses with mutations in the E3L gene as potential replication-competent, attenuated vaccines: scarification vaccination. Vaccine 26:2860-2872. http://dx.doi.org/10.1016/j.vaccine.2008.03.044.
49. Vijaysri S, Jentarra G, Heck MC, Mercer AA, McInnes CJ, Jacobs BL. 2008. Vaccinia viruses with mutations in the E3L gene as potential replication-competent, attenuated vaccines: intra-nasal vaccination. Vaccine 26:664-676. http://dx.doi.org/10.1016/j.vaccine.2007.11.045.
50. Yang D, Tamburro K, Dittmer D, Cui X, McVoy MA, Hernandez-Alvarado N, Schleiss MR. 2013. Complete genome sequence of pathogenic guinea pig cytomegalovirus from salivary gland homogenates of infected animals. Genome Announc 1(2):e00054-13. http://dx.doi.org/10.1128/genomeA.00054-13.
51. Perdiguero B, Esteban M. 2009. The interferon system and vaccinia virus evasion mechanisms. J Interferon Cytokine Res 29:581-598. http://dx.doi.org/10.1089/jir.2009.0073.
52. Yamada S, Fukuchi S, Hashimoto K, Fukui Y, Tsuda M, Kataoka M, Katano H, Inoue N. 2014. Guinea pig cytomegalovirus GP129/131/133, homologues of human cytomegalovirus UL128/130/131A, are necessary for infection of monocytes and macrophages. J Gen Virol 95:1376-1382. http://dx.doi.org/10.1099/vir.0.064527-0.
53. Cui X, Adler SP, Davison AJ, Smith L, Habib E-SE, McVoy MA. 2012 Bacterial artificial chromosome clones of viruses comprising the Towne cytomegalovirus vaccine. J Biomed Biotechnol 2012:428498. http://dx.doi.org/10.1155/2012/428498.
54. Cui X, Meza BP, Adler SP, McVoy MA. 2008. Cytomegalovirus vaccines fail to induce epithelial entry neutralizing antibodies comparable to natural infection. Vaccine 26:5760-5766. http://dx.doi.org/10.1016/j.vaccine.2008.07.092.
55. Olejniczak MJ, Choi KY, McVoy MA, Cui X, Schleiss MR. 2011. Intravaginal cytomegalovirus (CMV) challenge elicits maternal viremia and results in congenital transmission in a guinea pig model. Virol J 8:89. http://dx.doi.org/10.1186/1743-422X-8-89.
56. Schleiss MR. 2013. Developing a vaccine against congenital cytomegalovirus (CMV) infection: what have we learned from animal models? Where should we go next? Future Virol 8:1161-1182.